ZEPBOUND: payments to doctors
Payments that named ZEPBOUND as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $19.8M
- Providers
- 97,317
- Transactions
- 360,176
- Average per transaction
- $55
The per-transaction average — $55 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 97,317 providers the average total is $203, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $19,564,120 | 98.9% |
| Eli Lilly | $205,839 | 1.0% |
| Eli Lilly Export S.A. Puerto Rico Branch | $17,636 | 0.1% |